Selen plus is commonly used for managing symptomatic discomfort across key dermatological conditions. The medication is commonly used to help ease symptoms related to itching and flaking associated with certain scalp conditions and is relevant for easing symptoms of a specific fungal infection of the skin.

Management and Relief Domains

This medication is used for managing symptoms related to inflammatory or irritative states and is commonly used for conditions characterized by periods of heightened symptoms such as dandruff, Seborrheic Dermatitis, and Tinea Versicolor. It is relevant for managing the symptoms of persistent scaling and visible flaking in conditions like seborrhea, and is relevant for easing the associated scalp itching and irritation. For fungal skin issues, it is used for managing the fungal manifestations and may assist with improving the appearance of the discolored patches on the body. This action helps ease the overall symptom burden and supports general well-being during symptomatic phases.

---

Therapeutic Summary
Primary Symptoms	Chronic scaling, visible flaking, and itching.
Primary Benefit	Contributes to improved comfort and eases symptom load.
Relevant Context	Applied in scenarios requiring additional management of discomfort in recurrent conditions.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Selen plus?

The population eligibility for Selen plus (topical Selenium Sulfide) is strictly defined by regulatory guidelines to ensure appropriate use and safety. Eligibility is primarily determined by age, skin condition, and physiological status.

---

Contraindications and Restricted Use

Classification	Population/Condition
Absolute Contraindication	Individuals with a known hypersensitivity or allergy to selenium sulfide or any component of the formulation.
Use Prohibited	Application on areas of broken skin, acute inflammation, or skin exudation (weeping/oozing) due to the risk of increased systemic absorption.

---

Age and Physiological Eligibility

Adults and children 2 years of age and older are established populations for use. The safety and effectiveness of the 2.5% strength have not been established in infants (under 2 years old), restricting its use in this age group.

Use is restricted during pregnancy; the medicine is classified as Pregnancy Category C, and its use for large-surface application (such as tinea versicolor) is generally not recommended. Caution must also be exercised when the product is administered to a nursing woman.

Interactions with Other Medicines and Products

The regulatory profile for Selenium Sulfide Topical Suspension (Selen plus) documents a lack of known systemic drug–drug interactions, reflecting its localized application and minimal systemic absorption. Official government sources state that there are no known pharmacokinetic or pharmacodynamic interactions with other orally administered medicinal products, food, alcohol, or nutritional supplements.

Documented Interaction Constraints

The documented interaction patterns are primarily localized and condition-dependent, resulting in specific constraints for use.

Interaction Type	Constraint Statement
Exposure Modification Risk	Application to skin with acute inflammation or exudation (broken skin) increases the risk of systemic absorption of the active ingredient. Use is therefore restricted on compromised skin.
Timing Restriction	The product must not be applied for a period of two days before or after the hair is treated with chemicals, such as dyeing, tinting, permanent waving, or bleaching.
Substance Restriction	Metallic jewelry (e.g., gold and silver) must be removed prior to application to prevent discoloration or damage.

These constraints establish that the principal interaction concerns relate to procedural requirements and the integrity of the skin barrier, which modifies the risk of increased systemic exposure.

The mechanism of Selenium Sulfide ( SeS2) involves a dual, localized pharmacodynamic action targeting both cellular and microbial factors within the epidermis.

Cytostatic Modulation of Epidermal Cell Turnover

The compound exerts an antimitotic action on the hyperproliferative basal keratinocytes (epidermal cells). The drug's dissociation products interfere with key enzyme systems necessary for cell division, thereby slowing the mitotic rate in the basal layer of the skin. This effect promotes the normalization of the epidermal cell cycle, which results in a modified physiological state within the epidermis and a physiological decrease in the production of shed corneocyte clusters.

Targeted Inhibition of Fungal Metabolic Pathways

Selenium Sulfide acts as an antifungal agent by targeting specific yeasts, primarily Malassezia species. This is achieved through the disruption of essential fungal metabolic pathways and enzyme function, leading to the inhibition of yeast growth and replication. This targeted interference results in a physiological reduction of the microbial burden on the skin surface, which reduces the output of microbial metabolites that can trigger localized cellular inflammatory responses.

How to Use Selen plus

Selen plus, containing the active ingredient Selenium Sulfide, is strictly administered via the topical route to the skin and scalp. The medication is commercially available as a medicated suspension or shampoo, commonly found in 1% and 2.5% concentrations. Standard guidelines establish two distinct dosing regimens based on the area of application.

For scalp conditions, such as seborrheic dermatitis, the initial course involves applying 1 to 2 teaspoonfuls (approximately 5–10 mL) twice weekly for a duration of two weeks. Once this initial phase is complete, the frequency transitions to an intermittent, as-needed maintenance pattern to sustain control. In contrast, the protocol for Tinea Versicolor treatment requires a sufficient quantity to be applied to the body once daily for a fixed, short-term duration of seven consecutive days.

Usage Entity Category	Official Instruction
Preparation	The suspension must be shaken well before use.
Contact Time (Scalp)	Allow to remain on the scalp for 2 to 3 minutes prior to rinsing.
Contact Time (Body)	Allow to remain on the skin for 10 minutes prior to rinsing.
Post-Use Requirement	The treated area must be thoroughly rinsed after application.
Age Restriction	Not established for use in infants (under 2 years of age).

Connection to the overall use protocol: The established instructions provide a structured, two-phase treatment model defined by distinct frequency and contact-time requirements. This protocol ensures the proper mechanical preparation of the suspension, governs the precise duration the product must remain on the skin for two separate indications, and mandates thorough rinsing to conclude the procedure. The administration method is strictly topical and non-systemic, with use frequency varying between intensive initial courses and intermittent, long-term maintenance applications.

Research Evidence / Overview of Studies for Selen plus

Research Studies Examining Seborrheic Dermatitis and Chronic Scalp Flaking

Research has extensively examined the use of the agent in randomized controlled trials (RCTs), comparative clinical studies, and observational settings. These studies primarily explored short-term changes in adult subjects with conditions such as chronic scaling and flaking (dandruff) and seborrheic dermatitis.

Studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states, using clinical scores over short periods (typically four weeks). Findings describe symptom patterns and reported measurements of change in scalp scores compared to other topical agents. Evidence remains limited regarding long-term changes and the longevity of observed outcomes, as follow-up durations were restricted.

Research Studies Examining Tinea Versicolor

Clinical research was evaluated in trials for Tinea Versicolor, examining mycological clearance (laboratory confirmation of fungal resolution) and lesion status in patients across a broad range of ages. Trials reported documented clearance outcomes following short treatment courses (7–14 days). Comparative findings against other antifungals were mixed.

Follow-up research tracked recurrence for up to two years, which was frequently observed in the studied populations. Systematic reviews sometimes describe the quality of evidence as low due to differences in study bias.

Research in Special Populations and Evidence Gaps

Specific trials explored the agent’s role as an adjunct to systemic oral medication in children with Tinea Capitis, examining mycological cure rates during the concurrent treatment phase. Research does not determine whether an individual will respond similarly, and limited information is available regarding its performance as a primary treatment for this condition.

Overall, long-term effects are not fully established beyond existing trials, and data for certain groups remain insufficient. Review findings indicate that the consistency of evidence varies, and comparative evidence against all possible alternative agents is lacking in some areas.

Common questions about Selen plus (FAQ)

Q: If I miss an application of Selen plus, what should I do?

A: According to the official product instructions, if a missed application is noticed, the product information indicates that the application may be used as soon as it is remembered. However, if the time is almost right for the next scheduled application, the missed dose should be skipped, and the patient may resume their regular schedule. It is noted that double or extra applications should not be used to make up for a missed application.

---

Q: What should I do if Selen plus accidentally gets into my eyes?

A: It is advised to prevent the product from getting into the eyes during use. If accidental contact occurs, the product information recommends rinsing the eyes thoroughly with water. If irritation persists or is severe, contact with a healthcare professional may be appropriate.

---

Q: What should I do if the product causes excessive skin irritation or burning?

A: Regulatory documents indicate that the application of Selen plus may produce skin irritation or sensitivity reactions. If sensitivity reactions, such as redness or burning, are observed, the product's use should be discontinued. Any concerning or severe reactions should be reported to a healthcare provider for evaluation.

---

Q: How long after the first application will I start to see results for dandruff?

A: The official product protocol establishes an initial, more intensive application frequency. This phase is designed to achieve initial control of conditions like dandruff and seborrheic dermatitis. Following this initial phase, the required frequency is adjusted to an intermittent, as-needed schedule for long-term maintenance.

Mandatory Storage and Disposal Requirements

Official regulatory documents define strict environmental controls and disposal methods for Selen plus (Selenium Sulfide Topical Suspension) to maintain product stability and safety.

Storage Category	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F).
Prohibitions	Do not freeze and protect from excessive heat.
Container	Keep the container tightly closed and away from moisture.
Child Safety	Keep out of the reach of children.

The disposal of unused or expired suspension should follow U.S. Food and Drug Administration (FDA) guidance. The product is not recommended for flushing. Preferred disposal methods include authorized drug take-back programs or mixing the medicine with unappealing substances (like dirt or coffee grounds) in a sealed container before placing it in household trash.